Pfizer Inc. said Monday that results from its most recent human trials on its coronavirus vaccine shows it is more than 90% effective.
The results are based on 94 trial subjects who were infected by the coronavirus and subsequently developed at least one symptom.
Pfizer said it is now on track to ask health regulators for permission to begin distributing and selling the vaccine – which is two shots weeks apart – by the end of the month, if continued trials demonstrate that the vaccine is safe.
The Food and Drug Administration requires a company to monitor at least 50% of a study's subjects for side effects for a period of two months before making a safety assessment of the vaccine. Pfizers says it is in on track to collect that data by next week, and could apply for FDA emergency authorization soon after that.
